Experts and Doctors on erythropoietin in Göttingen, Lower Saxony, Germany


Locale: Göttingen, Lower Saxony, Germany
Topic: erythropoietin

Top Publications

  1. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009;40:e647-56 pubmed publisher
    ..Based on analysis of total intent-to-treat and per-protocol populations only, this is a negative trial that also raises safety concerns, particularly in patients receiving systemic thrombolysis. ..
  2. Ehrenreich H, Kastner A, Weissenborn K, Streeter J, Sperling S, Wang K, et al. Circulating damage marker profiles support a neuroprotective effect of erythropoietin in ischemic stroke patients. Mol Med. 2011;17:1306-10 pubmed publisher
    ..In particular, reduction in the neuronal damage marker UCH-L1 may reflect neuroprotection by EPO. ..
  3. Offen N, Flemming J, Kamawal H, Ahmad R, Wolber W, Geis C, et al. Effects of erythropoietin in murine-induced pluripotent cell-derived panneural progenitor cells. Mol Med. 2013;19:399-408 pubmed publisher
    ..In differentiating cultures EPO facilitated neurodifferentiation as assessed by the increased number of ?-III-tubulin positive neurons. Our results show that EPO inhibits iPS pNPC self-renewal and promotes neurogenesis. ..
  4. Hassouna I, Sperling S, Kim E, Schulz Schaeffer W, Rave Frank M, Hasselblatt M, et al. Erythropoietin augments survival of glioma cells after radiation and temozolomide. Int J Radiat Oncol Biol Phys. 2008;72:927-34 pubmed publisher
    ..EPOR and EGFRvIII expression did not correlate. EPO is unlikely to appreciably influence basal glioma growth. However, concomitant use of EPO with irradiation/chemotherapy in GBM patients is not advisable. ..
  5. Ehrenreich H, Fischer B, Norra C, Schellenberger F, Stender N, Stiefel M, et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain. 2007;130:2577-88 pubmed
    ..There were no adverse events, no safety concerns and a surprisingly low need of blood-lettings. This first pilot study demonstrates the necessity and feasibility of controlled trials using high-dose rhEPO in chronic progressive MS...
  6. SIREN A, Radyushkin K, Boretius S, Kämmer D, Riechers C, Natt O, et al. Global brain atrophy after unilateral parietal lesion and its prevention by erythropoietin. Brain. 2006;129:480-9 pubmed
    ..This demonstrates that a localized brain lesion is a primary cause of delayed global neurodegeneration that can be efficiently counteracted by neuroprotection. ..
  7. Ramadori P, Sheikh N, Ahmad G, Dudas J, Ramadori G. Hepatic changes of erythropoietin gene expression in a rat model of acute-phase response. Liver Int. 2010;30:55-64 pubmed publisher
    ..These results suggest that EPO may be added to the increasing group of positive acute-phase proteins and the liver might represent the major source of the hormone under these conditions in the rat. ..
  8. Wustenberg T, Begemann M, Bartels C, Gefeller O, Stawicki S, Hinze Selch D, et al. Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia. Mol Psychiatry. 2011;16:26-36, 1 pubmed publisher
    ..These findings suggest that a neuroprotective strategy is effective against common pathophysiological features of schizophrenic patients, and strongly encourage follow-up studies to optimize EPO treatment dose and duration. ..
  9. Knabe W, SIREN A, Ehrenreich H, Kuhn H. Expression patterns of erythropoietin and its receptor in the developing spinal cord and dorsal root ganglia. Anat Embryol (Berl). 2005;210:209-19 pubmed

More Information


  1. Hagemeyer N, Boretius S, Ott C, Von Streitberg A, Welpinghus H, Sperling S, et al. Erythropoietin attenuates neurological and histological consequences of toxic demyelination in mice. Mol Med. 2012;18:628-35 pubmed publisher
    ..These findings underscore the value of future therapeutic strategies for multiple sclerosis based on EPO or EPO variants. ..
  2. Kastner A, Grube S, El Kordi A, Stepniak B, Friedrichs H, Sargin D, et al. Common variants of the genes encoding erythropoietin and its receptor modulate cognitive performance in schizophrenia. Mol Med. 2012;18:1029-40 pubmed publisher
    ..Together, these findings reveal a role of endogenous EPO/EPOR for cognition, at least in schizophrenic patients. ..
  3. Adamcio B, Sargin D, Stradomska A, Medrihan L, Gertler C, Theis F, et al. Erythropoietin enhances hippocampal long-term potentiation and memory. BMC Biol. 2008;6:37 pubmed publisher
    ..These mechanisms of action of EPO have to be further exploited for treating neuropsychiatric diseases. ..
  4. Schettler V, Wieland E. A case report of darbepoetin treatment in a patient with sickle cell disease and chronic renal failure undergoing regular hemodialysis procedures that induce a dose-dependent extension of blood transfusion intervals. Ther Apher Dial. 2009;13:80-2 pubmed publisher
    ..To substantiate our observation, further investigations are needed with more SCD patients undergoing regular hemodialysis treatment. ..
  5. El Kordi A, Radyushkin K, Ehrenreich H. Erythropoietin improves operant conditioning and stability of cognitive performance in mice. BMC Biol. 2009;7:37 pubmed publisher
    ..Early erythropoietin treatment leads to lasting improvement of cognitive performance in healthy mice. This finding should be exploited in novel treatment strategies for brain diseases. ..
  6. Ramadori P, Ahmad G, Ramadori G. Cellular and molecular mechanisms regulating the hepatic erythropoietin expression during acute-phase response: a role for IL-6. Lab Invest. 2010;90:1306-24 pubmed publisher
    ..The increase of HIF-2alpha, predominantly expressed in endothelial cells and fibroblast-like cells, seems not to be affected by the lack of IL-6. ..
  7. Sargin D, El Kordi A, Agarwal A, Muller M, Wojcik S, Hassouna I, et al. Expression of constitutively active erythropoietin receptor in pyramidal neurons of cortex and hippocampus boosts higher cognitive functions in mice. BMC Biol. 2011;9:27 pubmed publisher
    ..This property of EPOR signaling should be exploited for defining novel strategies to therapeutically enhance cognitive performance in disease conditions. ..
  8. Knabe W, Knerlich F, Washausen S, Kietzmann T, Siren A, Brunnett G, et al. Expression patterns of erythropoietin and its receptor in the developing midbrain. Anat Embryol (Berl). 2004;207:503-12 pubmed
    ..Whether the observed expression patterns of EPO and EPOR may reflect EPO-mediated trophic and/or antiapoptotic effects on neurons is discussed. ..